Compare TRIP & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIP | MGTX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2011 | 2018 |
| Metric | TRIP | MGTX |
|---|---|---|
| Price | $14.55 | $12.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $14.40 | ★ $24.57 |
| AVG Volume (30 Days) | ★ 2.6M | 817.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,556,000,000.00 | $81,391,000.00 |
| Revenue This Year | $3.33 | $141.38 |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $9.01 | $6.62 |
| 52 Week High | $20.16 | $15.35 |
| Indicator | TRIP | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 51.57 |
| Support Level | $13.04 | $8.84 |
| Resistance Level | $15.33 | $15.35 |
| Average True Range (ATR) | 0.57 | 0.67 |
| MACD | -0.08 | -0.20 |
| Stochastic Oscillator | 75.41 | 20.85 |
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025, and TheFork, its dining brand, represented 12% of sales.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.